Bempedoic Acid Gets ‘Huge’ Win for Primary Prevention in the Statin-Intolerant
SAN DIEGO — Bempedoic acid (Nexletol) prevented cardiovascular events in high-risk, statin-intolerant patients who had not yet had an event, a subgroup analysis from the CLEAR Outcomes trial confirmed. In these patients, bempedoic acid was associated with a large decrease in risk of major adverse cardiovascular events (MACE) compared with placebo over a median 39.9 […]